Skip to main content

Andera Partners — Portfolio

Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.

63
Companies
$3.9B
Total invested
$81.0M
Avg. check
28
Industries
Biotechnology 16Health Care 12Medical 8Therapeutics 5Medical Device 5Biopharma 4+22 more
Founder contacts

Verified emails & LinkedIn for founders across this portfolio.

jane@on●●●●●●●.com
linkedin.com/in/●●●●●●
Verified contacts, updated monthly
Get instant access →

Portfolio companies

Showing 124 of 63
Qualisteo
September 2023

Qualisteo, is a company based in Nice (France) specialized in energy efficiency for industrial and tertiary sites

Consulting · Nice$5.4M Venture - Series Unknown
ImCheck Therapeutics
August 2024

ImCheck Therapeutics designs and develops immunotherapeutic antibodies for the treatment of cancer and autoimmune disease.

Biopharma · Marseille$22.4M Grant
Axonics Modulation Technologies
August 2022

Axonics Modulation Technologies is a pre-revenue company developing novel implantable neuromodulation.

Health Diagnostics · Irvine$111.7M Post-IPO Equity
T-knife
August 2021

T-knife is a developer of T cell receptors intended for T cell therapy of cancer.

Biotechnology · Berlin$110.0M Series B
Cyllene Therapeutics
July 2026

Cyllene Therapeutics is a French biotechnology business that is pioneering a novel approach termed pinpoint gene therapy.

Biotechnology · Paris$37.7M Series C
Lhyfe
July 2025

Lhyfe is a producer and supplier of green hydrogen, generated through renewable energy sources.

Energy · Nantes$2.9M Equity Crowdfunding
Mineralys Therapeutics
June 2026

Mineralys Therapeutics is a clinical-stage biopharmaceutical company committed to developing therapy for the treatment of hypertension.

Biopharma · Radnor$500.0M Post-IPO Debt
Dualyx
May 2023

Dualyx engages in the discovery and development of biologicals for the treatment of autoimmune and rare diseases.

Biotechnology · Ghent$43.5M Series A
Rivermark Medical
May 2026

Rivermark Medical develops a minimally-invasive treatment for Benign Prostatic Hyperplasia (BPH) that restores urinary function.

Health Care · Milwaukee$20.0M Series D
Ariceum Therapeutics
April 2023

Ariceum Therapeutics focuses on diagnosis and precision treatment of neuroendocrine and certain other aggressive, hard-to-treat cancers.

Biotechnology · Berlin$25.0M Series A
MMI
February 2024

MMI is focused on advancing robotic technology for soft tissue open surgery with the world's smallest wristed instruments.

Health Care · Pisa$110.0M Series C
Evommune
February 2026

Evommune is a biotechnology company that develops therapeutics that halt progressive disease and address their symptoms.

Biotechnology · Palo Alto$125.0M Post-IPO Equity
Adcytherix
October 2025

Adcytherix is a biopharmaceutical firm that specializes in the development of new antibody drug conjugates (ADC).

Biotechnology · Marseille$122.4M Series A
Tubulis
October 2025

Tubulis generates antibody-drug conjugates with unique properties for solid tumor indications.

Biotechnology · Munich$400.6M Series C
ENYO Pharma
June 2025

ENYO Pharma is a biopharmaceutical company based in Lyon, France.

Biopharma · Lyon$6.9M Series C
Qovoltis
October 2024

Qovoltis offers smart charging solutions for electric vehicles and a mobile app for remote management.

Electric Vehicle · Arcueil$49.7M Series B
Skysun
September 2024

Skysun is a financial institution that provides financial solutions and services to the solar energy sector.

Energy · Genappe$18.7M Series A
SciRhom
July 2024

SciRhom is a biotech enterprise that translate advanced scientific findings into game-changing therapies for autoimmune diseases.

Biotechnology · Martinsried$68.1M Series A
Greywolf Therapeutics
May 2024

We are advancing novel antigen modulation technology that controls T cells to guide the immune system.

Biotechnology · Abingdon$50.0M Series B
Alveus Therapeutics
January 2026

Alveus Therapeutics is a clinical-stage biotech company developing therapies for obesity and metabolic diseases.

Biotechnology · Philadelphia$197.0M Series A
Spiro Medical
January 2026

Spiro Medical is a medical device company developing a groundbreaking Pulmonary Neuromodulation (PNM) System for asthma treatment.

Biotechnology · Menlo Park$67.0M Series A
Amolyt Pharma
January 2023

Amolyt Pharma specializes in peptides for the treatment of rare endocrine and metabolic disorders.

Biotechnology · Écully$138.6M Series C
Kestra Medical Technologies, Inc.
December 2025

Kestra Medical Technologies offers wearable medical devices which collects, store, and communicate patients vital performance data.

Health Care · Kirkland$138.0M Post-IPO Equity
TargED Biopharmaceuticals
December 2025

TargED Biopharmaceuticals is a biotechnology company that develops first-in-class biological drugs to improve treatment of thrombosis.

Biopharma · Utrecht$25.3M Series A

Where Andera Partners invests

Biotechnology16
Health Care12
Medical8
Therapeutics5
Medical Device5
Biopharma4

About Andera Partners's portfolio

How many companies has Andera Partners invested in?

Andera Partners has invested in 63 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.

What industries does Andera Partners invest in?

Andera Partners's top investment sectors include Biotechnology, Health Care, Medical, Therapeutics, Medical Device. The firm invests across 28 different industry categories.

What is Andera Partners's largest investment?

Among tracked funding rounds, Mineralys Therapeutics received $500.0M in a Post-IPO Debt round. Andera Partners's total known invested capital is $3.9B.

What is the average investment size for Andera Partners?

Andera Partners's average investment size is $81.0M across its portfolio of 63 companies.

What are Andera Partners's most recent investments?

Recent Andera Partners portfolio additions include Qualisteo, ImCheck Therapeutics, Axonics Modulation Technologies, T-knife, Cyllene Therapeutics. These companies were founded in 2020 or later.

Reach the founders behind these 63 companies
Verified emails and LinkedIn profiles, updated monthly.
Get instant access →